Skip to main content

Table 1 Clinicopathological characteristics in 389 BLCA patients according to the FGFR3 status at the collection of biospecimens

From: The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer

  

FGFR3 mutations (nonsynonymous/indels)

FGFR3 fusion

Variables

n = 389

mutation -n = 308 (79%)

mutation + n = 81 (21%)

p value

fusion -n = 372 (96%)

fusion + n = 17 (4%)

p value

Sex (%)

 male

306 (79)

243 (79)

63 (78)

 

291 (78)

15 (88)

 

 female

83 (21)

65 (21)

18 (22)

0.83

81 (22)

2 (12)

0.29

Age (mean ± SD)

 

70 ± 11.2

69 ± 11.1

70 ± 11.5

0.52

70 ± 11.2

69 ± 10.6

0.82

Smoking history (%)

 never

132 (34)

102 (33)

30 (37)

 

127 (34)

5 (29)

 

 past/current

242 (62)

193 (63)

49 (60)

 

231 (62)

11 (65)

 

 unnown

15 (4)

13 (4)

2 (3)

0.64

14 (4)

1 (6)

0.86

Clinical Stage (%)

 cN0M0

315 (81)

244 (79)

71 (87)

 

301 (81)

14 (82)

 

 cN1M0

51 (13)

44 (14)

7 (9)

 

50 (13)

1 (6)

 

 cNxM1

23 (6)

20 (7)

3 (4)

0.2

21 (6)

2 (12)

0.43

Muscle invasion (%)

 NMIBC

124 (32)

75 (24)

49 (61)

 

115 (31)

9 (53)

 

 MIBC

265 (68)

233 (76)

32 (39)

 < 0.001*

257 (69)

8 (47)

0.06

Histological variants (%)

 no

345 (89)

270 (88)

75 (93)

 

328 (88)

17 (100)

 

 yes

44 (11)

38 (12)

6 (7)

0.19

44 (12)

0 (0.0)

0.04*

Concomittant CIS (%)

 no

333 (86)

258 (84)

75 (93)

 

320 (86)

13 (76)

 

 yes

56 (14)

50 (16)

6 (7)

0.03*

52 (14)

4 (24)

0.31

Pathological grade (WHO2004)

 low

40 (10)

19 (6)

21 (26)

 

37 (10)

3 (18)

 

 high

349 (90)

289 (94)

60 (74)

 < 0.001*

335 (90)

14 (82)

0.35

Lymphovascular invasion

 no

179 (46)

121 (39)

58 (72)

 

169 (45)

10 (59)

 

 yes

210 (54)

187 (61)

23 (28)

 < 0.001*

203 (55)

7 (41)

0.28

Median follow-up period

  (months: [IQR])

31 [15, 44]

29 [14, 42]

38 [20, 45]

 

31 [15, 42]

47 [23, 55]

 
  1. BLCA Bladder cancer, FGFR3 Fibroblast growth factor receptor 3, TACC3 Transforming acidic coiled-coil containing protein 3, SD Standard deviation, NMIBC Non-muscle invasive bladder cancer, MIBC Muscle invasive bladder cancer, CIS Carcinoma in situ, WHO World Health Organization, BCG Bacille de Calmette et Guérin, IQR Interquartile range
  2. *Denotes p < 0.05